Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection

Stuart Byrne, Takamichi Baba, Nao Kawaguchi, Atsuko Yamamoto, Yoshiyuki Nakano, Caroline Dorrepaal, Brandon Londt, Alex Mann, Nikolay Veselinski, Takeki Uehara

Open source

DOI: 10.1093/cid/ciag367
Published: 2026-06-15
Container: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag367,
  title = {Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection},
  author = {Stuart Byrne and Takamichi Baba and Nao Kawaguchi and Atsuko Yamamoto and Yoshiyuki Nakano and Caroline Dorrepaal and Brandon Londt and Alex Mann and Nikolay Veselinski and Takeki Uehara},
  year = {2026},
  journal = {Clinical Infectious Diseases},
  doi = {10.1093/cid/ciag367},
  url = {https://doi.org/10.1093/cid/ciag367}
}

RIS

TY  - JOUR
TI  - Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection
AU  - Stuart Byrne
AU  - Takamichi Baba
AU  - Nao Kawaguchi
AU  - Atsuko Yamamoto
AU  - Yoshiyuki Nakano
AU  - Caroline Dorrepaal
AU  - Brandon Londt
AU  - Alex Mann
AU  - Nikolay Veselinski
AU  - Takeki Uehara
PY  - 2026
JO  - Clinical Infectious Diseases
DO  - 10.1093/cid/ciag367
UR  - https://doi.org/10.1093/cid/ciag367
ER  -

APA

Byrne, S., Baba, T., Kawaguchi, N., Yamamoto, A., Nakano, Y., Dorrepaal, C., Londt, B., Mann, A., Veselinski, N., & Uehara, T. (2026). Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag367

Source records

crossref · retrieved 2026-09-27T14:30:48.316Z